证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2024-01 | --- | --- | --- | --- | --- | |-------------------------|---------------------------------------------|------------------|---------------------|-------| | | | | | | | 投资者关系活动 | √特定对象调研 □分析师会议 | | | | | 类别 | □媒体采访 □业绩说明会 □新闻发布会 □路演活动 | | | | | | □现场参观 | | | | | | □其他 （请文字说明其他活动内容） | | | | | | 中信建投证券股份有限公司 王在存 | | | | | 参与单位名称及 人员姓名 | 中信建投证券股份有限公司 李虹达 | | | | | 时间 | 2024 年 12 月 6 日 | | | | | 地点 | 上海市浦东新区瑞庆路 | 号公司四楼会议室 | | | | 上市公司接待人 | 上海凯利泰医疗科技股份有限 ...

上海凯利泰医疗科技股份有限公司 2024 年第三季度报告 证券代码：300326 证券简称：凯利泰 公告编号：2024-049 上海凯利泰医疗科技股份有限公司 2024 年第三季度报告 | --- | --- | --- | |---------------------------------|--------|-------| | 股票代码： | 300326 | | | 股票简称：凯利泰 | | | | 披露日期：二○二四年十月二十三日 | | | 上海凯利泰医疗科技股份有限公司 2024 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 2 上海凯利泰医疗科技股份有限公司 2024 年第三季度报告 一、主要财务数据 （一） 主要 ...

上海凯利泰医疗科技股份有限公司 2024 年半年度报告 上海凯利泰医疗科技股份有限公司 二○二四年半年度报告 股票代码：300326 股票简称：凯利泰 披露日期：二○二四年八月二十七日 1 上海凯利泰医疗科技股份有限公司 2024 年半年度报告全文 2 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人袁征、主管会计工作负责人李元平及会计机构负责人(会计主 管人员)李元平声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投 资者的实质承诺，敬请投资者注意投资风险。公司在本报告第三节"管理层 讨论与分析-公司面临的风险和应对措施"部分，详细描述了公司经营中可能 存在的风险及应对措施，敬请投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 上海凯利泰医疗科技股份有限公司 2024 年半年度报告全文 目录 | --- | |------ ...

上海凯利泰医疗科技股份有限公司 2024 年第一季度报告 证券代码：300326 证券简称：凯利泰 公告编号：2024-026 上海凯利泰医疗科技股份有限公司 二○二四年第一季度报告 股票代码：300326 股票简称：凯利泰 披露日期：二○二四年四月二十四日 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 2 上海凯利泰医疗科技股份有限公司 2024 年第一季度报告 一、主要财务数据 1 上海凯利泰医疗科技股份有限公司 2024 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | - ...

上海凯利泰医疗科技股份有限公司2023年年度报告 上海凯利泰医疗科技股份有限公司 二○二三年年度报告 ...

上海凯利泰医疗科技股份有限公司 2023 年第三季度报告 证券代码: 300326 证券简称:凯利泰 公告编号: 2023-036 上海凯利泰医疗科技股份有限公司 二〇二三年第三季度报告 凯 利 示 股票代码: 300326 股票简称:凯利泰 披露日期: 二〇二三年十月二十六日 l 上海凯利泰医疗科技股份有限公司 2023 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大 遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完 整。 3.第三季度报告是否经过审计 □是 否 2 上海凯利泰医疗科技股份有限公司 2023 年第三季度报告 一、主要财务数据 (一) 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 口是 ☑否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- ...

上海凯利泰医疗科技股份有限公司 2023 年半年度报告全文 上海凯利泰医疗科技股份有限公司 二〇二三年半年度报告 K 凯 利 泰 股票代码: 300326 股票简称:凯利泰 披露日期: 二〇二三年八月二十五日 1 上海凯利泰医疗科技股份有限公司 2023 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人袁征、主管会计工作负责人李元平及会计机构负责人(会计主 管人员)李元平声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资 者的实质承诺，敬请投资者注意投资风险。公司在本报告第三节 十、公司面临 的风险和应对措施，详细描述了公司经营中可能存在的风险及应对措施，敬请 投资者关注相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 上海凯利泰医疗科技股份有限公司 2023 年半年度报告全文 | | | | 第一节 重要提示 ...

上海凯利泰医疗科技股份有限公司 2023 年第一季度报告 证券代码: 300326 证券简称:凯利泰 公告编号: 2023-020 上海凯利泰医疗科技股份有限公司 二〇二三年第一季度报告 凯 利 泰 股票代码: 300326 股票简称:凯利泰 披露日期: 二〇二三年四月二十六日 上海凯利泰医疗科技股份有限公司 2023 年第一季度报告 上海凯利泰医疗科技股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 2 （二） 非经常性损益项目和金额 适用 □不适用 | | | 单位：元 | | --- | --- | --- | | 项目 | 本报告期金额 | 说明 | | 非流动资产处置损益（包括已计提资 | 30,16 ...

Financial Performance - Revenue for 2022 was RMB 1,166.04 million, a decrease of 8.08% year-over-year[6] - Net profit attributable to shareholders was a loss of RMB -21.28 million, a decrease of 113.16% year-over-year[6] - Revenue in 2022 decreased by 8.08% to 1,166,042,082.06 yuan compared to 1,268,579,510.95 yuan in 2021[26] - Net profit attributable to shareholders in 2022 was -21,282,494.18 yuan, a decrease of 113.16% compared to 161,775,976.76 yuan in 2021[26] - Net cash flow from operating activities in 2022 was 236,756,963.51 yuan, a decrease of 37.39% compared to 378,155,561.13 yuan in 2021[26] - Basic earnings per share in 2022 was -0.0296 yuan, a decrease of 113.21% compared to 0.2241 yuan in 2021[26] - Total assets at the end of 2022 were 3,412,148,611.26 yuan, a decrease of 2.78% compared to 3,509,647,722.46 yuan at the end of 2021[26] - Revenue in Q4 2022 was 237,655,218.77 yuan, the lowest among the four quarters[29] - Net profit attributable to shareholders in Q4 2022 was -218,097,422.86 yuan, the only quarter with a negative profit[29] - Revenue for the reporting period was RMB 11,660.421 million, a decrease of 8.08% year-on-year[94] - Net profit attributable to shareholders of the listed company was RMB -212.825 million, a decrease of 113.16% year-on-year[94] - Vertebroplasty minimally invasive business achieved sales revenue of RMB 539.3335 million, a decrease of 2.22% year-on-year[96] - Low-temperature radiofrequency business achieved sales revenue of RMB 205.4081 million, an increase of 25.05% year-on-year[96] - Trauma and spine orthopedic implant business achieved sales revenue of RMB 106.1527 million, a decrease of 31.08% year-on-year[97] - Medical device trade business achieved sales revenue of RMB 140.3668 million, a decrease of 27.98% year-on-year[97] - Disinfection and sterilization service revenue decreased by 19.58% to 155.01 million yuan in 2022, compared to 192.75 million yuan in 2021[98] - The fair value of the investment in Kahtnu Surgical Inc. was written down to zero, resulting in a fair value change loss of 18.25 million yuan, compared to a gain of 28.15 million yuan in 2021[98] - Net cash flow from operating activities decreased by 37.39% to 236.76 million yuan in 2022, primarily due to reduced sales revenue and government subsidies[99] - R&D investment decreased by 7.54% to 68.65 million yuan in 2022, accounting for 5.89% of operating revenue, an increase of 0.04 percentage points compared to the previous year[102] - Total operating revenue decreased by 8.08% to 1.17 billion yuan in 2022, with domestic market revenue decreasing by 11.89% to 998.30 million yuan[109] - Revenue from radiofrequency ablation products increased by 25.05% to 205.41 million yuan in 2022[109] - Revenue from orthopedic spine and trauma products decreased by 31.08% to 106.15 million yuan in 2022[109] - Revenue from the international market increased by 23.77% to 167.74 million yuan in 2022[109] - Revenue from other businesses increased by 78.78% to 19.77 million yuan in 2022[109] - Medical device manufacturing revenue decreased by 2.18% to 850,894,350.98 yuan, with a gross margin of 76.88%[110] - Medical device trade revenue dropped by 27.98% to 140,366,820.31 yuan, with a gross margin of 14.73%[110] - Domestic market revenue declined by 11.89% to 998,297,178.14 yuan, while the foreign market revenue increased by 23.77% to 167,744,903.91 yuan[110] - Sales volume of medical device manufacturing decreased by 44.00% to 2,965,281 units, and production volume dropped by 55.63% to 2,863,751 units[111] - Medical device trade sales volume surged by 1,708.54% to 3,722,399 units, and production volume increased by 1,112.21% to 4,102,017 units[111] - Material costs for medical device manufacturing increased by 5.52% to 108,723,283.21 yuan, accounting for 25.72% of total operating costs[113] - Depreciation and amortization costs for medical device manufacturing rose by 13.98% to 12,136,318.60 yuan[113] - Sales expenses decreased by 1.30% year-over-year, amounting to 283,916,369.87 RMB[120] - Management expenses increased by 25.51% year-over-year, reaching 154,375,192.25 RMB[120] - Financial expenses decreased by 55.14% year-over-year, totaling 4,058,568.53 RMB[121] - R&D expenses decreased by 12.00% year-over-year, amounting to 61,401,962.45 RMB[121] - Income tax expenses decreased by 47.50% year-over-year, totaling 21,689,257.32 RMB[121] - The net cash flow from operating activities in 2022 was RMB 236,756,963.51, a decrease of 37.39% compared to 2021, mainly due to reduced sales revenue and government subsidies[126][127] - The net cash flow from investment activities in 2022 was RMB -163,776,092.95, a decrease of 49.96% compared to 2021, primarily due to reduced cash inflows from investment recoveries and disposals[127] - The net cash flow from financing activities in 2022 was RMB -104,092,116.51, an increase of 56.44% compared to 2021, mainly due to reduced bank loan repayments and interest payments[128] - Operating cash flow for the reporting period was RMB 236.757 million, while net profit was RMB -23.9528 million, with a significant difference due to a goodwill impairment provision of RMB 197.9948 million for Aidier and a fair value loss of RMB 18.0198 million for Kahtnu Surgical Inc[129] - Investment income was RMB -10.6531907 million, a 470.64% change, mainly due to equity method investment losses of RMB 16.9288 million and disposal of subsidiaries[131] - Fair value change loss was RMB -18.24878 million, a 806.21% change, as the investment in Kahtnu Surgical Inc was written down to zero due to operational difficulties[132] - Asset impairment loss was RMB -201.05935488 million, a 8,882.55% change, including goodwill impairment of RMB 197.9948 million and fixed asset impairment of RMB 1.7416 million[132] - Accounts receivable decreased by 19.04% to RMB 367.50530952 million, mainly due to reduced receivables and bad debt provisions[134] - Inventory increased by 18.13% to RMB 346.83154410 million, influenced by external environment and centralized procurement policies[134] - Short-term loans decreased by 6.35% to RMB 170.00646496 million, as the company repaid bank loans[134] - Long-term loans decreased by RMB 100 million, reclassified to current liabilities due to maturity within one year[134] - Trading financial assets increased by 48.71% to RMB 264.4 million, mainly due to an increase in undeposited bank wealth management products[134] - Notes receivable increased to RMB 9.15221257 million, representing undeposited bank acceptance bills[134] - Prepaid accounts increased by 46.61% compared to the beginning of the period, mainly due to increased prepayments by subsidiaries Runzhi Tai and Jienuo Medical[136] - Other current assets increased by 38.74% compared to the beginning of the period, mainly due to increased unverified input tax, prepaid corporate income tax, and reduced VAT credit balance[136] - Other non-current financial assets increased by 34.58% compared to the beginning of the period, primarily due to a RMB 48.9544 million investment in Japan Hemotech Co., Ltd. and a write-down of investment in Kahtnu Surgical Inc. to zero[136] - Employee compensation payable increased by 56.58% compared to the beginning of the period, mainly due to unpaid wages and bonuses at the end of the reporting period[136] - Taxes payable decreased by 56.95% compared to the beginning of the period, mainly due to a reduction in unpaid VAT and corporate income tax[136] - Deferred income decreased by 32.92% compared to the beginning of the period, mainly due to the completion and transfer of some government subsidy projects to other income accounts[136] - Treasury stock decreased by 99.56% compared to the beginning of the period, mainly due to the failure to meet the unlocking conditions of the third phase of restricted stock and subsequent repurchase and cancellation[137] - Other comprehensive income increased by 148.47% compared to the beginning of the period, mainly due to foreign currency translation differences[137] - Overseas assets accounted for 8.87% of the company's net assets, with Elliquence, LLC generating a net profit of RMB 32.3849 million[137] - The fair value of other non-current financial assets decreased by RMB 18.01982 million during the reporting period[140] - Restricted assets as of the reporting period: Cash and cash equivalents of 4,003,008.83 yuan due to pledged loan guarantees, long-term equity investments of 410,550,965.39 yuan, investment properties of 26,932,208.68 yuan, fixed assets of 127,860,357.13 yuan, and intangible assets of 9,652,573.98 yuan[141] - Total investment in the reporting period increased by 46.18% to 75,214,398.41 yuan compared to the same period last year[144] - Aidi reported revenue of 80.98 million yuan and a net loss of 3.68 million yuan for the reporting period[150] - Elliquence, LLC reported revenue of 168.58 million yuan and net profit of 32.38 million yuan for the reporting period[150] - Jienuo Medical Management Group reported revenue of 192.03 million yuan and net profit of 5.33 million yuan for the reporting period[150] - Elliquence, LLC achieved revenue of 168.58 million RMB and net profit of 32.38 million RMB in the reporting period[159] - Jienuo Medical achieved revenue of 192.03 million RMB and net profit of 5.33 million RMB in the reporting period[161] Centralized Procurement Impact - The company's orthopedic spine, radiofrequency ablation, and trauma products were affected by centralized procurement policies, leading to a significant drop in prices[6] - The company's products were selected in centralized procurement, but the reduced prices negatively impacted the existing distribution system and profit model[6] - In 2021, the average price reduction for orthopedic trauma medical consumables in a 12-province joint procurement was 88.65%, significantly impacting the industry[40] - The company's subsidiary, Aideal, ranked high in clinical demand and bid prices for ordinary bone plate systems and intramedullary nail systems in the procurement[41] - The company faced significant challenges due to the expansion and implementation of centralized procurement policies for high-value medical consumables[92] - The company and its subsidiaries participated in the national orthopedic spine consumables centralized procurement, but the actual procurement volume for 2022 was 0 due to the procurement not being executed[71] - The company anticipates increased competition in the domestic orthopedic market, particularly in the vertebral augmentation minimally invasive surgery segment[181] - The company faces risks from orthopedic centralized procurement policies, which may lead to significant price reductions and potential impacts on profitability[178] Product Portfolio and Innovation - The company's main business is in the production, R&D, sales, and services of orthopedic implant medical devices, including spine minimally invasive products and orthopedic trauma implant devices[37] - The company's product line has expanded from a single spine product to a comprehensive range of orthopedic high-value consumables, including trauma, spine, and minimally invasive joint products, with a focus on developing minimally invasive orthopedic products under the Kelii and Aidier brands[45] - The company's core product, the vertebral augmentation minimally invasive surgery system, has achieved stable growth, with sales expanding from tertiary hospitals to local hospitals, opening up a broader market space[53] - The company completed the acquisition of Elliquence, LLC, which specializes in high-frequency low-temperature, anatomical (monopolar), and coagulation (monopolar and bipolar) technologies, enhancing its presence in the orthopedic equipment sector[49] - The company established a joint venture with Italian company TECRES S.P.A. to develop and produce bone cement products, including spine bone cement, high-viscosity bone cement, antibacterial bone cement, and joint bone cement, enriching its product line[53] - The company acquired 56% of Jienuo Medical to enhance its market competitiveness and profitability through medical sterilization services, which help hospitals reduce operating costs and improve resource allocation efficiency[51] - The company strengthened its distribution network by establishing a joint venture with Sinopharm Holding Medical Devices Co., Ltd., leveraging Sinopharm's brand and financial advantages to expand its market share in medical device sales[50] - The company's subsidiary, Aidier, focuses on the development, production, and sales of orthopedic implants and surgical instruments, with products widely used in trauma and spine surgeries[47] - The company's acquisition of Elliquence, LLC has facilitated the integration of its existing orthopedic resources, enabling the rapid advancement of Elliquence's products in the domestic market[53] - The company has built a comprehensive marketing system in the spinal minimally invasive field, including team building, commercial channel construction, and academic system development, with a professional and market-oriented sales team[54] - The company's joint venture with TECRES S.P.A. has introduced advanced bone cement products and technologies, strengthening its strategic layout and technical accumulation in the medical device field[46] - The company has extensive experience in product promotion, particularly in the vertebral augmentation market, which has established its leading position and accumulated significant expert resources and distribution channels[55] - The company has strengthened its competitive advantage by continuously introducing high-level talent in R&D, quality, and market sales since its IPO in June 2012[56] - The company maintains a strict and standardized quality control system, emphasizing quality as its core value and implementing rigorous supervision across all operational stages[57] - The company has a comprehensive product portfolio covering orthopedic trauma, spine, minimally invasive orthopedic, and radiofrequency ablation, with plans to expand into more innovative minimally invasive products[59] - The company has 4 domestic medical device registration certificates under application, including the Vertebral Lamina Fixation Plate System and Metal Bone Pin[61] - The company has 49 overseas medical device registration applications pending as of December 31, 2022, including products like the KMC Kyphoplasty System and Balloon Catheter, primarily for spinal and orthopedic procedures[62] - The Surgi-Max Ultra series, a new generation of high-frequency hosts for surgical procedures, has been submitted for registration in Egypt, Nicaragua, and Ukraine[63] - The KMC Kyphoplasty System, designed for minimally invasive spinal surgeries, is under review in Pakistan for treating osteoporotic vertebral compression fractures[62] - The Balloon Catheter and Bone Filler Device, both for spinal surgeries, are under review in Turkey[62] - The Surgi-Max Ultra series is classified as IIb and III, targeting advanced surgical applications in orthopedics, arthroscopy, and neurosurgery[63] - The company is expanding its product portfolio with devices like the Vertebral Osteotome and Suture Anchors, currently under review in Turkey and Iran respectively[62] - The Titanium Mesh System and Integrated External Fixation devices are under review in Thailand for cranial and orthopedic applications[63] - The Anatomic Metal Locking Plate & Screw System and Anterior Spinal Plate & Screw System are under review in Thailand for orthopedic and spinal fixation[63] - The Centrum Fusion Device, designed for spinal fusion surgeries, is under review in Thailand[63] - The company is focusing on international market expansion with registration applications in multiple countries including Pakistan, Turkey, Iran, Thailand, Egypt, Nicaragua, and Ukraine[62][63] - Surgi-Max® Ultra series, a new generation of high-frequency hosts, has been submitted for approval in multiple countries including the Dominican Republic, Belarus, and the Philippines[64][30][31] - Trigger-Flex® bipolar system, designed for soft tissue coagulation/shrinkage, has been submitted for approval in countries such as Nicaragua, Egypt, and the Philippines[32][33][34] - Disc-FX family system, used for ablation and coagulation of intervertebral disc material, has been submitted for approval in countries including the Dominican Republic, Nicaragua, and Belarus[37][38][39] - Endiscope, suitable for visualization during spinal endoscopy and minimally invasive surgeries, has been submitted for approval in countries such as Egypt, Japan, and the Dominican Republic[42][43][44] - Elliquence's imported products (endoscopic surgical instruments, spinal endoscopes, high-frequency surgical equipment, nucleus forceps) have completed registration and are expected to fill the gap in the company's spinal endoscopy product line[122] - The expandable interbody fusion device and supporting instruments are in the product design phase, aiming to enhance the company's spine product offerings[122] - The lamina fixation plate system is under registration review, which will benefit the company's spine product series[122] - The company has obtained a Class III medical device registration certificate for spinal bone cement through its joint venture with TECRES S.P.A and will accelerate the registration of other bone cement products[176] Subsidiaries and Acquisitions - The company's subsidiary, Jiangsu Aidier Medical Technology Co., Ltd., won bids for various orthopedic trauma products in the 8th round of volume-based procurement in Jiangsu Province, with prices ranging from 1,716 RMB to 2,450 RMB per product[78][79

证券代码：300326 证券简称：凯利泰 上海凯利泰医疗科技股份有限公司 投资者关系活动记录表 编号：2015-02 | --- | --- | --- | |-----------------------------|------------------------------|-----------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中信证券 研究部研究员 田加强 | | | 人员姓名 | 中信证券 研究部研究员 许拓 | | | 时间 | 2015 年 7 月 24 | 日 | | 地点 | | 上海凯利泰医疗科技股份有限公司 4 楼 | | 上市公司接待人 | 董事会秘书 丁魁 | | | 员姓名 | | | | | | | | 投资者关系活动 主要内容介绍 | 详见附件 | | | 附 件 ...